Smithfield Trust Co. maintained its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) during the second quarter, Holdings Channel reports. The institutional investor owned 1,200 shares of the medical instruments supplier’s stock at the end of the second quarter. Smithfield Trust Co.’s holdings in West Pharmaceutical Services were worth $113,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the company. Burt Wealth Advisors increased its position in shares of West Pharmaceutical Services by 38,540.0% in the first quarter. Burt Wealth Advisors now owns 1,932 shares of the medical instruments supplier’s stock worth $158,000 after buying an additional 1,927 shares during the period. Harfst & Associates Inc. purchased a new position in shares of West Pharmaceutical Services during the first quarter worth approximately $186,000. Tyers Asset Management LLC increased its position in shares of West Pharmaceutical Services by 17.6% in the first quarter. Tyers Asset Management LLC now owns 2,464 shares of the medical instruments supplier’s stock worth $201,000 after buying an additional 368 shares during the period. Cambridge Investment Research Advisors Inc. increased its position in shares of West Pharmaceutical Services by 1.6% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 2,569 shares of the medical instruments supplier’s stock worth $210,000 after buying an additional 40 shares during the period. Finally, CIBC Asset Management Inc purchased a new position in shares of West Pharmaceutical Services during the second quarter worth approximately $223,000. 91.35% of the stock is currently owned by institutional investors.

Shares of West Pharmaceutical Services, Inc. (NYSE:WST) opened at 86.36 on Thursday. West Pharmaceutical Services, Inc. has a 1-year low of $70.17 and a 1-year high of $99.91. The stock has a market capitalization of $6.39 billion, a P/E ratio of 37.06 and a beta of 1.10. The stock has a 50 day moving average of $92.61 and a 200-day moving average of $88.81.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.01. The company had revenue of $397.60 million for the quarter, compared to analysts’ expectations of $406 million. West Pharmaceutical Services had a net margin of 11.42% and a return on equity of 14.02%. The firm’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period last year, the company earned $0.59 EPS. Equities research analysts predict that West Pharmaceutical Services, Inc. will post $2.70 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Wednesday, October 18th will be issued a dividend of $0.14 per share. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.13. This represents a $0.56 annualized dividend and a dividend yield of 0.65%. The ex-dividend date is Tuesday, October 17th. West Pharmaceutical Services’s dividend payout ratio is presently 22.22%.

COPYRIGHT VIOLATION NOTICE: “West Pharmaceutical Services, Inc. (NYSE:WST) Stake Held by Smithfield Trust Co.” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.watchlistnews.com/west-pharmaceutical-services-inc-nysewst-stake-held-by-smithfield-trust-co/1466923.html.

WST has been the topic of a number of analyst reports. Zacks Investment Research raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a research note on Friday, June 23rd. BidaskClub downgraded shares of West Pharmaceutical Services from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and set a $90.00 target price on shares of West Pharmaceutical Services in a research note on Thursday, June 8th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $90.18.

In other news, CFO William J. Federici sold 54,996 shares of the stock in a transaction dated Thursday, May 18th. The shares were sold at an average price of $95.45, for a total transaction of $5,249,368.20. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 1.90% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.